Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![ars_pharma Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1230566656524640256.png) ARS Pharmaceuticals [@ars_pharma](/creator/twitter/ars_pharma) on x XXX followers
Created: 2025-07-18 13:38:52 UTC

This content is intended for U.S. audiences only.
 
#NEWS:  Our licensing partner ALK has received approval in the United Kingdom for our treatment for allergic reactions (anaphylaxis).
 
Read more:
 
#AllergyCare #Investors $SPRY

![](https://pbs.twimg.com/media/GwJNUkcXsAAhR1x.jpg)

XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1946203016828256495/c:line.svg)

**Related Topics**
[$spry](/topic/$spry)
[united kingdom](/topic/united-kingdom)

[Post Link](https://x.com/ars_pharma/status/1946203016828256495)

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

ars_pharma Avatar ARS Pharmaceuticals @ars_pharma on x XXX followers Created: 2025-07-18 13:38:52 UTC

This content is intended for U.S. audiences only.

#NEWS: Our licensing partner ALK has received approval in the United Kingdom for our treatment for allergic reactions (anaphylaxis).

Read more:

#AllergyCare #Investors $SPRY

XXX engagements

Engagements Line Chart

Related Topics $spry united kingdom

Post Link

post/tweet::1946203016828256495
/post/tweet::1946203016828256495